转移性鼻咽癌的化学治疗进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v4i2.4999
Abstract
鼻咽癌发病率占头颈部恶性肿瘤第一位,对放化疗敏感。随着精准放疗技术及综合治疗模式开展,鼻咽癌预后明显提高。但转移性鼻咽癌预后差,成为鼻咽癌治疗难点。全身化疗是转移性鼻咽癌最基本的有效治疗方式。常用铂类为基础的联合方案,其中PF方案是最经典的一线化疗方案,近年研究显示GP方案化疗疗效优于传统方案,延长了生存期,TP方案也是一线优化推荐；维持化疗在转移性鼻咽癌中也发挥了重要作用,可控制疾病进展；一线及维持化疗失败后转移性鼻咽癌,二线及后线化疗是一种补救治疗,改善患者生存质量。随着分子靶向及免疫治疗在各种实体瘤深入研究,它们与化疗的联合治疗鼻咽癌也已成为新的研究方向,但化疗仍然是转移性鼻咽癌治疗的基石。
Keywords
转移性鼻咽癌；化学治疗；一线化疗；维持化疗；二线及后线化疗
Full Text
PDF - Viewed/Downloaded: 0 TimesIndexation
Download Index RecordReferences
[1] 李斌.恩度联合化疗治疗转移性鼻咽癌的Ⅱ期临床研究[J].中国肿瘤临床,2012.39(24):2022-2025.
[2] 潘琦津,龚建忠,韦燕.转移性鼻咽癌维持治疗研究现状及进展[J].现代肿瘤医学,2018.26(21):3505-3508.
[3] Li, Y.H.Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma[J].Cancer Chemother Pharmacol,2008.62(3):539-44.
[4] Ji, J.H.A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07- 01)[J].Eur J Cancer,2012.48(17):3198-204.
[5] Chen, C.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasophary ngeal carcinoma[J].Cancer Chemother Pharmacol,2013.71(2):371-8.
[6] Zhang,L.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J].Lancet,2016.388(10054):1883-1892.
[7] 杨慧.吉西他滨/多西他赛联合铂类一线治疗转移性鼻咽癌的临床对照研究[J].现代肿瘤医学,2018,26(24):3932-3936.
[8] Huang, Y.Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma[J]. BMC Cancer,2016.16:464.
[9] Sun, X.S.The role of capecitabine as maintenance ther apy in de novo metastatic nasopharyngeal carcinoma: A propen sity score matching study[J].CancerCommun(Lond),2020.40(1):32-42.
[10] Liu, G.Y.Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagn osed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy:A Phase 3 Randomized Clinical Trial. [J].JAMA Oncol,2022.
[11] 韦柳君.一线化疗临床获益后替吉奥维持治疗在转移性鼻咽癌患者中的应用效果[J].广西医学,2021.43(15):1789-1791+1800.
[12] 廖恺.初诊转移性鼻咽癌一线治疗后维持治疗研究[J].实用医学杂志,2020,36(14):1929-1933.
[13] 杨慧.转移性鼻咽癌一线化疗后替吉奥维持治疗的多中心随机对照研究[J].中国肿瘤临床,2021,48(01):25-29.
[14] Zhang, L.Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcin oma after the failure of platinum-based chemotherapy[J]. Cancer Chemother Pharmacol,2008.61(1):33-8.
[15] 钟大妮.吉西他滨联合长春瑞滨二线治疗转移性鼻咽癌的临床疗效[J].中国癌症防治杂志,2018,10(04):295-298.
[16] 元建华.吉西他滨联合替吉奥治疗铂类方案化疗失败晚期鼻咽癌患者临床观察[J].中华肿瘤防治杂志,2019.26(3):170-174.
[2] 潘琦津,龚建忠,韦燕.转移性鼻咽癌维持治疗研究现状及进展[J].现代肿瘤医学,2018.26(21):3505-3508.
[3] Li, Y.H.Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma[J].Cancer Chemother Pharmacol,2008.62(3):539-44.
[4] Ji, J.H.A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07- 01)[J].Eur J Cancer,2012.48(17):3198-204.
[5] Chen, C.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasophary ngeal carcinoma[J].Cancer Chemother Pharmacol,2013.71(2):371-8.
[6] Zhang,L.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J].Lancet,2016.388(10054):1883-1892.
[7] 杨慧.吉西他滨/多西他赛联合铂类一线治疗转移性鼻咽癌的临床对照研究[J].现代肿瘤医学,2018,26(24):3932-3936.
[8] Huang, Y.Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma[J]. BMC Cancer,2016.16:464.
[9] Sun, X.S.The role of capecitabine as maintenance ther apy in de novo metastatic nasopharyngeal carcinoma: A propen sity score matching study[J].CancerCommun(Lond),2020.40(1):32-42.
[10] Liu, G.Y.Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagn osed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy:A Phase 3 Randomized Clinical Trial. [J].JAMA Oncol,2022.
[11] 韦柳君.一线化疗临床获益后替吉奥维持治疗在转移性鼻咽癌患者中的应用效果[J].广西医学,2021.43(15):1789-1791+1800.
[12] 廖恺.初诊转移性鼻咽癌一线治疗后维持治疗研究[J].实用医学杂志,2020,36(14):1929-1933.
[13] 杨慧.转移性鼻咽癌一线化疗后替吉奥维持治疗的多中心随机对照研究[J].中国肿瘤临床,2021,48(01):25-29.
[14] Zhang, L.Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcin oma after the failure of platinum-based chemotherapy[J]. Cancer Chemother Pharmacol,2008.61(1):33-8.
[15] 钟大妮.吉西他滨联合长春瑞滨二线治疗转移性鼻咽癌的临床疗效[J].中国癌症防治杂志,2018,10(04):295-298.
[16] 元建华.吉西他滨联合替吉奥治疗铂类方案化疗失败晚期鼻咽癌患者临床观察[J].中华肿瘤防治杂志,2019.26(3):170-174.
Copyright © 2022 熊新拓, 向志碧, 彭小宁
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License